


CONCLUSION

In view of the above arguments and comments, Applicants respectfully submit that the present case is in condition for allowance, and as such a Notice of Allowance is respectfully earnestly solicited. Should there be any questions regarding these amendments and remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
Barry J. Marenberg, Reg. No. 40,715
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Date: October 4, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification at page 6, lines 17-21, please amend as follows:

FIG. 1 illustrates the targeted sites for the antigenic fragments (SEQ ID NO:1);

FIG. 2 illustrates the effect of 1 mg/ml of antibodies raised against D and L forms of A β (16-21) (SEQ ID NO:7) on fibrillogenesis;

FIG. 3 illustrates the effect of 0.5 mg/ml of antibodies raised against D and L forms of A β (16-21) (SEQ ID NO:7) on fibrillogenesis;

In the specification at page 7, lines 1-2, please amend as follows:

FIG. 7 illustrates the response of rabbits to KLH-conjugated all-L and all-D KLVFFA (SEQ ID NO:7).

TRA 1717674v1